NASDAQ: PLRZPolyrizon Ltd Stock
$1.06-0.03 (-2.75%)
Updated Oct 28, 2025
PLRZ Price
$1.06
Fair Value Price
$0.85
Market Cap
$6.23M
52 Week Low
$0.55
52 Week High
$1,200.00
P/E
-0.01x
P/B
0.34x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$1.13M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$3M
Beta
0.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PLRZ Overview
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PLRZ's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PLRZ
Ranked#240 of 487
Ranked#240 of 487
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.10 | A | |
| $12.63 | A | |
| $7.24 | A |
Be the first to know about important PLRZ news, forecast changes, insider trades & much more!
PLRZ News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PLRZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PLRZ ($1.06) is overvalued by 24.15% relative to our estimate of its Fair Value price of $0.85 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PLRZ ($1.06) is not significantly undervalued (24.15%) relative to our estimate of its Fair Value price of $0.85 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PLRZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PLRZ due diligence checks available for Premium users.
Valuation
PLRZ fair value
Fair Value of PLRZ stock based on Discounted Cash Flow (DCF)
Price
$1.06
Fair Value
$0.85
Overvalued by
24.15%
PLRZ ($1.06) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PLRZ ($1.06) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PLRZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PLRZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
-89.89x
Market
40.54x
PLRZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.34x
Industry
4.99x
PLRZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PLRZ's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PLRZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.7M
Liabilities
$364.0k
Debt to equity
0.02
PLRZ's short-term assets ($16.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLRZ's short-term assets ($16.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLRZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PLRZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PLRZ vs Biotech Stocks
Polyrizon Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.